| scholarly article | Q13442814 |
| P2093 | author name string | Katherine A MacLean | |
| Matthew W Johnson | |||
| Roland R Griffiths | |||
| Thomas E Prisinzano | |||
| Chad J Reissig | |||
| P2860 | cites work | Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist | Q24535736 |
| Human hallucinogen research: guidelines for safety | Q24600704 | ||
| Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans | Q28191252 | ||
| Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance | Q28250818 | ||
| Psychopharmacology of the hallucinogenic sage Salvia divinorum | Q28276228 | ||
| Salvia divinorum: effects and use among YouTube users | Q33520598 | ||
| Acute Physiologic and Chronic Histologic Changes in Rats and Mice Exposed to the Unique Hallucinogen Salvinorin A | Q33973923 | ||
| Interactions between kappa opioid agonists and cocaine. Preclinical studies | Q33981445 | ||
| Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors | Q33984723 | ||
| Salvia divinorum and salvinorin A: new pharmacologic findings | Q34292784 | ||
| Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats | Q34459404 | ||
| Adolescent salvia substance abuse | Q34627065 | ||
| Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor | Q35082154 | ||
| Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). | Q36038503 | ||
| Salvia divinorum: exposures reported to a statewide poison control system over 10 years | Q37600149 | ||
| Kappa opioids and the modulation of pain | Q37725698 | ||
| Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. | Q40585107 | ||
| Use patterns and self-reported effects of Salvia divinorum: an internet-based survey | Q42971596 | ||
| Pattern of use and subjective effects of Salvia divinorum among recreational users. | Q43842086 | ||
| Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale | Q43842193 | ||
| Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward | Q44336472 | ||
| The plant-derived hallucinogen, salvinorin A, produces ?-opioid agonist-like discriminative effects in rhesus monkeys | Q44343280 | ||
| Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo | Q44346801 | ||
| Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse | Q44350970 | ||
| Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist | Q44351693 | ||
| Persistent psychosis associated with salvia divinorum use. | Q45943426 | ||
| Toxic psychosis after intake of the hallucinogen salvinorin A | Q83296403 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Salvia divinorum | Q320584 |
| opioid | Q427523 | ||
| P304 | page(s) | 150-155 | |
| P577 | publication date | 2010-12-04 | |
| P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
| P1476 | title | Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum | |
| P478 | volume | 115 |
| Q55058151 | "Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. |
| Q41814963 | A Report of Nausea and Vomiting with Discontinuation of Chronic Use of Salvia divinorum |
| Q35837572 | A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats |
| Q58102187 | Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence |
| Q37681438 | Activation of μ-opioid receptors inhibits calcium-currents in the vestibular afferent neurons of the rat through a cAMP dependent mechanism |
| Q91635326 | Acute Effects of 2C-E in Humans: An Observational Study |
| Q52316991 | Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. |
| Q43842140 | Acute and post-acute behavioral and psychological effects of salvinorin A in humans |
| Q44344643 | Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability |
| Q46178251 | Analysis of Salvinorin A in urine using microextraction in packed syringe and GC-MS/MS. |
| Q48727079 | Analysis of the smoke of cigarettes containing Salvia divinorum. |
| Q57255770 | Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism |
| Q35996706 | Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo |
| Q46880304 | Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q38862468 | Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions |
| Q44350143 | Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats |
| Q30447153 | Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans |
| Q24616738 | Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects |
| Q28084198 | Drug models of schizophrenia |
| Q42600971 | Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice |
| Q24631675 | Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines |
| Q36894509 | Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. |
| Q44346829 | Kappa Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition |
| Q28075656 | Kappa Opioids, Salvinorin A and Major Depressive Disorder |
| Q37451366 | LC-MS/MS quantification of salvinorin A from biological fluids |
| Q34632744 | Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats. |
| Q30402789 | Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution |
| Q39548034 | Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. |
| Q38778876 | Molecular Signaling Pathways Behind the Biological Effects of Salvia Species Diterpenes in Neuropharmacology and Cardiology |
| Q27300685 | Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans |
| Q36899819 | Neoclerodanes as atypical opioid receptor ligands |
| Q30467220 | Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A |
| Q33725088 | Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace |
| Q34939810 | Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A |
| Q35840042 | Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A |
| Q35126018 | Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. |
| Q35065030 | Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers |
| Q64062550 | Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action |
| Q57888900 | Salvia divinorum: toxicological aspects and analysis in human biological specimens |
| Q34401390 | Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. |
| Q26781580 | Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders |
| Q38262913 | Salvinorin A: A Mini Review of Physical and Chemical Properties Affecting Its Translation from Research to Clinical Applications in Humans. |
| Q36363810 | Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans |
| Q100428072 | The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain |
| Q38575828 | The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series |
| Q28235852 | The claustrum's proposed role in consciousness is supported by the effect and target localization of Salvia divinorum |
| Q47862941 | The role of psychedelics in palliative care reconsidered: A case for psilocybin |
| Q28257248 | The subjective experience of acute, experimentally-induced Salvia divinorum inebriation |
| Q37621277 | Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans |
| Q36129657 | Use of Salvia divinorum in a nationally representative sample |
Search more.